Author

Dania Annuar

New York University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:deep learning· 1

Frequent Co-Authors

Abhimanyu AmarnaniiD· 1 shared Accelerating Medicines Partnership RA/SLE Network· 1 shared Andrea FavaiD· 1 shared Andy ZhaoiD· 1 shared Anne DavidsoniD· 1 shared Arnon AraziiD· 1 shared Betty DiamondiD· 1 shared Brad H. RoviniD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Abhimanyu AmarnaniORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Rethinking the Benign Nature of Class II Lupus Nephritis

Jasmine Shwetar, Andrea Fava, Sarah Keegan, Philip M. Carlucci, Jeffrey N. Dudley, Lodoe Lama, Hemant Suryawanshi, Pavel S Morozov, Briana J. Mullins, Abhimanyu Amarnani, Linda Procell, Dania Annuar, Siddarth Gurajala, Peter Izmirly, Judith A. James, , Kelly V. Ruggles

This study defines the single-cell landscape of Class II lupus nephritis and identifies fibroblast transcriptional programs and chronicity index as potential predictors of kidney outcomes.

bioRxiv · Sep 18, 2026 · PreprintGenomics

Specific Aneuploidies Predict Immune Evasion and Poor Immunotherapy Response in Melanoma

Lizabeth Katsnelson, Shini Chen, Dania Annuar, Jesús M. Rangel-Valenzuela, Andy Zhao, Joanne Xiu, David Fenyö, Joy J. Bianchi, Teresa Davoli

This study identifies chromosome 1q gain as a biomarker for poor immunotherapy response in melanoma by linking aneuploidies to immune evasion mechanisms.

bioRxiv · Apr 15, 2026 · PreprintCancer Biology